MPHARM 287 Seminar > Leo Petrossian & James Bowie

  • Tuesday, April 21, 2015
  • 1:00 -3:00 pm
  • BSRB room 154
  • 12-077 Ctr For Health Sciences
  • Los Angeles, CA 90095

Join the Business of Science Center on April 21st, 2015 in the Biomedical Science Research Library room 154 at 1:00. We will have Drs. Leo Petrossian and James Bowie as our guest speakers. Dr. Petrossian will share his experiences on startups and Neural Analytics. Dr. Bowie will be presenting his technology, Synthetic biochemistry for the production of high value products.

1:00 – 1:30 pm – Dr. James Bowie
2:00 – 3:00 pm – Dr. Leo Petrossian

James Bowie, PhD


Dr. James Bowie has been a professor of chemistry and biochemistry at UCLA for the last 21 years. Traditionally, Dr. Bowie’s research was focused on investigating basic scientific questions of protein – protein interactions, protein structure and membrane protein stability but recently his lab has ventured out into mere applied science and has created a project around synthetic biochemistry. Synthetic biochemistry is a technique that uses purified enzymatic extracts to recapitulate enzymatic pathways without the complexity of a cell. Because of this, synthetic biochemistry can perform complex biotransformations with increased speed and yield compared to in vivo attempts at metabolic engineering.

Synthetic Biochemistry for the production of high value products

The Bowie lab has pioneered a synthetic biochemistry approach for the conversion of simple sugars into high value products, specifically bioplastic and terpenes. Currently the terpene segment of the scent and fragrance industry is a $944M per year market that is dominated by simple monoterpenes and will grow to $1.144B by 2017. Bioplastics on the other hand represent an estimated $7.8B industry by 2018 that is growing at around 20% compound annual growth rate (CAGR). This array of products will give INvizyne the opportunity to enter relatively high cost markets quickly, while developing its Synthetic Biochemisty platform. As the technology becomes more robust, INvizyne can work down the value chain to the low cost/high volume products that necessitate economies of scale and yield to be competitive.

Leo Petrossian, PhD, MBA

Leo Petrossian

Dr. Leo Petrossian is the co-founder and CEO of Neural Analytics, Inc., a medical device startup focused on the development of a product that will allow first responders and clinicians to diagnose the severity of a brain injury in any setting quickly, accurately and inexpensively. Prior to starting Neural Analytics in 2012, Dr. Petrossian was the co-founder and CTO of Custom Nanotech Consulting; a firm dedicated to helping nanotechnology startups overcome their unique prototyping challenges during the early stages of venture initiation. Before co-founding Custom Nanotech Consulting, he was the Director of Nanofabrication at Nabsys for 4 years, where he was responsible for device design, fabrication, testing and outsourcing, among many other duties.

Dr. Petrossian earned his MBA from the UCLA Anderson School of Management in 2014 and earned his PhD & MS in Biomolecular Nanotechnology & Solid-State Device Physics as an NSF IGERT fellow at Arizona State University in 2007. Leo also holds a double B.S. in Electrical Engineering & Biomedical Engineering from California State University, Long Beach.